| Officer | Age | In this role | Joined | Pay | Source |
|---|---|---|---|---|---|
|
Michael Davidson
Also a director
Chief Executive Officer
|
69 | Not stated | Not stated | Not reported | |
|
Ian Somaiya
Chief Financial Officer
|
52 |
Since 2023
3 years
|
2023 | Not reported | |
|
Johannes Jacob Pieter Kastelein
Chief Scientific Officer
Title from the Form 4 dated Sep 30, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Robert W. Gunning
Vice President, Controller
Title from the Form 4 dated Sep 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
John Kastelein
Also a director
Executive officer
|
72 | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Investor Rights Agreement with lock-up restrictions on Ordinary Shares and registration rights for former NewAmsterdam Pharma shareholders
Underwritten secondary offering of 13,857,415 Ordinary Shares at $11.50 per share; the Company sold no shares and received no proceeds
Indemnification agreements providing for indemnification and advancement of expenses
Loading...
